Prime-Boost Approach

We are committed to realizing the full potential of oncolytic virotherapy.

To augment the anti-tumor response in harder-to-treat cancers, we are leveraging the administration of mRNA-based therapeutic cancer vaccines to PRIME a robust T cell response against tumor antigens before using our HSV-1 to BOOST the anti-tumor effect.

Why mRNA cancer vaccines:

Through strategic collaborations, we are well-positioned to build a next-generation mRNA cancer vaccine to complement our oncolytic HSV-1 platform.